Cargando…

The Efficacy of Fibroblast Growth Factor for the Treatment of Chronic Vocal Fold Scarring: From Animal Model to Clinical Application

OBJECTIVES: This study assessed the regenerative efficacy of basic fibroblast growth factor (FGF) in a rabbit model of chronic vocal fold scarring and then confirmed its utility and safety in a prospective trial of patients with this condition. METHODS: FGF was injected three times, at 1-week interv...

Descripción completa

Detalles Bibliográficos
Autores principales: Ban, Myung Jin, Park, Jae Hong, Kim, Jae Wook, Park, Ki Nam, Lee, Jae Yong, Kim, Hee Kyung, Lee, Seung Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Otorhinolaryngology-Head and Neck Surgery 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678041/
https://www.ncbi.nlm.nih.gov/pubmed/27671715
http://dx.doi.org/10.21053/ceo.2016.00941
_version_ 1783277355376050176
author Ban, Myung Jin
Park, Jae Hong
Kim, Jae Wook
Park, Ki Nam
Lee, Jae Yong
Kim, Hee Kyung
Lee, Seung Won
author_facet Ban, Myung Jin
Park, Jae Hong
Kim, Jae Wook
Park, Ki Nam
Lee, Jae Yong
Kim, Hee Kyung
Lee, Seung Won
author_sort Ban, Myung Jin
collection PubMed
description OBJECTIVES: This study assessed the regenerative efficacy of basic fibroblast growth factor (FGF) in a rabbit model of chronic vocal fold scarring and then confirmed its utility and safety in a prospective trial of patients with this condition. METHODS: FGF was injected three times, at 1-week intervals, into a chronic vocal fold scar created in a rabbit model. After 1 month, mRNA level of procollagen I, hyaluronic acid synthetase 2 (HAS 2), and matrix metalloproteinase 2 (MMP 2) were analyzed by real-time polymerase chain reaction. The relative densities of hyaluronic acid (HA) and collagen were examined 3 months post-injection. From April 2012 to September 2014, a prospective clinical trial was conducted at a tertiary hospital in Korea. FGF was injected into the mild vocal fold scar of 17 consecutive patients with a small glottic gap. The patients underwent perceptual, stroboscopic, acoustic aerodynamic test, and Voice Handicap Index (VHI) survey prior to and 3, 6, and 12 months after FGF injection. RESULTS: FGF injection of the vocal fold scar decreased the density of collagen and increased mRNA level of HAS 2 and MMP 2 expression significantly compared to the control group injected with phosphate buffered solution in a rabbit model (P<0.05). In the clinical trial, significant improvements in the majority of the subjective and objective voice parameters were registered 3 months after FGF injection and were maintained at 12 months. Complications associated with the FGF injections, such as granuloma, were not observed during the follow-up period. CONCLUSION: Based on the animal model and the prospective clinical trial, vocal fold injections of FGF in patients with mild chronic vocal fold scarring can significantly improve voice quality for as long as 1 year and without side effects. Our results recommend the use of FGF vocal fold injection as an alternative treatment modality for mild chronic vocal fold scarring.
format Online
Article
Text
id pubmed-5678041
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Korean Society of Otorhinolaryngology-Head and Neck Surgery
record_format MEDLINE/PubMed
spelling pubmed-56780412017-12-01 The Efficacy of Fibroblast Growth Factor for the Treatment of Chronic Vocal Fold Scarring: From Animal Model to Clinical Application Ban, Myung Jin Park, Jae Hong Kim, Jae Wook Park, Ki Nam Lee, Jae Yong Kim, Hee Kyung Lee, Seung Won Clin Exp Otorhinolaryngol Original Article OBJECTIVES: This study assessed the regenerative efficacy of basic fibroblast growth factor (FGF) in a rabbit model of chronic vocal fold scarring and then confirmed its utility and safety in a prospective trial of patients with this condition. METHODS: FGF was injected three times, at 1-week intervals, into a chronic vocal fold scar created in a rabbit model. After 1 month, mRNA level of procollagen I, hyaluronic acid synthetase 2 (HAS 2), and matrix metalloproteinase 2 (MMP 2) were analyzed by real-time polymerase chain reaction. The relative densities of hyaluronic acid (HA) and collagen were examined 3 months post-injection. From April 2012 to September 2014, a prospective clinical trial was conducted at a tertiary hospital in Korea. FGF was injected into the mild vocal fold scar of 17 consecutive patients with a small glottic gap. The patients underwent perceptual, stroboscopic, acoustic aerodynamic test, and Voice Handicap Index (VHI) survey prior to and 3, 6, and 12 months after FGF injection. RESULTS: FGF injection of the vocal fold scar decreased the density of collagen and increased mRNA level of HAS 2 and MMP 2 expression significantly compared to the control group injected with phosphate buffered solution in a rabbit model (P<0.05). In the clinical trial, significant improvements in the majority of the subjective and objective voice parameters were registered 3 months after FGF injection and were maintained at 12 months. Complications associated with the FGF injections, such as granuloma, were not observed during the follow-up period. CONCLUSION: Based on the animal model and the prospective clinical trial, vocal fold injections of FGF in patients with mild chronic vocal fold scarring can significantly improve voice quality for as long as 1 year and without side effects. Our results recommend the use of FGF vocal fold injection as an alternative treatment modality for mild chronic vocal fold scarring. Korean Society of Otorhinolaryngology-Head and Neck Surgery 2017-12 2016-09-27 /pmc/articles/PMC5678041/ /pubmed/27671715 http://dx.doi.org/10.21053/ceo.2016.00941 Text en Copyright © 2017 by Korean Society of Otorhinolaryngology-Head and Neck Surgery This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Ban, Myung Jin
Park, Jae Hong
Kim, Jae Wook
Park, Ki Nam
Lee, Jae Yong
Kim, Hee Kyung
Lee, Seung Won
The Efficacy of Fibroblast Growth Factor for the Treatment of Chronic Vocal Fold Scarring: From Animal Model to Clinical Application
title The Efficacy of Fibroblast Growth Factor for the Treatment of Chronic Vocal Fold Scarring: From Animal Model to Clinical Application
title_full The Efficacy of Fibroblast Growth Factor for the Treatment of Chronic Vocal Fold Scarring: From Animal Model to Clinical Application
title_fullStr The Efficacy of Fibroblast Growth Factor for the Treatment of Chronic Vocal Fold Scarring: From Animal Model to Clinical Application
title_full_unstemmed The Efficacy of Fibroblast Growth Factor for the Treatment of Chronic Vocal Fold Scarring: From Animal Model to Clinical Application
title_short The Efficacy of Fibroblast Growth Factor for the Treatment of Chronic Vocal Fold Scarring: From Animal Model to Clinical Application
title_sort efficacy of fibroblast growth factor for the treatment of chronic vocal fold scarring: from animal model to clinical application
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678041/
https://www.ncbi.nlm.nih.gov/pubmed/27671715
http://dx.doi.org/10.21053/ceo.2016.00941
work_keys_str_mv AT banmyungjin theefficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication
AT parkjaehong theefficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication
AT kimjaewook theefficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication
AT parkkinam theefficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication
AT leejaeyong theefficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication
AT kimheekyung theefficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication
AT leeseungwon theefficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication
AT banmyungjin efficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication
AT parkjaehong efficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication
AT kimjaewook efficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication
AT parkkinam efficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication
AT leejaeyong efficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication
AT kimheekyung efficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication
AT leeseungwon efficacyoffibroblastgrowthfactorforthetreatmentofchronicvocalfoldscarringfromanimalmodeltoclinicalapplication